Anacor Pharmaceuticals (NASDAQ:ANAC) : The consensus price target for Anacor Pharmaceuticals (NASDAQ:ANAC) is $97.83 for the short term with a standard deviation of $2.45. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $99, however, the pessimist price target for the company is $95.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Mizuho Securities downgrades its outlook on Anacor Pharmaceuticals (NASDAQ:ANAC). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy. The rating by the firm was issued on May 18, 2016.
Anacor Pharmaceuticals (NASDAQ:ANAC): stock turned positive on Thursday. Though the stock opened at $99.23, the bulls momentum made the stock top out at $99.27 level for the day. The stock recorded a low of $99.2 and closed the trading day at $99.2, in the green by 0.03%. The total traded volume for the day was 5,373,306. The stock had closed at $99.17 in the previous days trading.
The company shares have rallied 28.21% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $156.93 and the one year low was seen on Apr 1, 2016. The 50-Day Moving Average price is $90.99 and the 200 Day Moving Average price is recorded at $81.44. On the companys insider trading activities, Bell Graeme, officer (Executive VP and CFO) of Anacor Pharmaceuticals, Inc., unloaded 751 shares at an average price of $99.28 on June 1, 2016. The total amount of the transaction was worth $74,559, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Companys lead product candidate, AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Companys product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development, which include AN3365. The Companys compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).